Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Preferred Stock Liabilities (2023 - 2025)

Rein Therapeutics (RNTX) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $45.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Preferred Stock Liabilities changed 0.0% to $45.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $45.0 million, a 0.0% change, with the full-year FY2024 number at $45.0 million, down 50.77% from a year prior.
  • Preferred Stock Liabilities was $45.0 million for Q3 2025 at Rein Therapeutics, roughly flat from $45.0 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $91.4 million in Q4 2023 to a low of $45.0 million in Q2 2024.
  • A 3-year average of $51.0 million and a median of $45.0 million in 2024 define the central range for Preferred Stock Liabilities.
  • Peak YoY movement for Preferred Stock Liabilities: tumbled 50.77% in 2024, then changed 0.0% in 2025.
  • Rein Therapeutics' Preferred Stock Liabilities stood at $91.4 million in 2023, then tumbled by 50.77% to $45.0 million in 2024, then changed by 0.0% to $45.0 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Preferred Stock Liabilities are $45.0 million (Q3 2025), $45.0 million (Q2 2025), and $45.0 million (Q1 2025).